These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 39415072)

  • 21. Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database.
    Younossi ZM; Stepanova M; Golabi P; Epstein RS; Strauss ME; Nader F; Racila A
    J Clin Gastroenterol; 2019 Oct; 53(9):693-698. PubMed ID: 30148766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort.
    Marschall HU; Henriksson I; Lindberg S; Söderdahl F; Thuresson M; Wahlin S; Ludvigsson JF
    Sci Rep; 2019 Aug; 9(1):11525. PubMed ID: 31395896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical profile of primary biliary cirrhosis that was diagnosed as symptomatic primary biliary cirrhosis according to the revised diagnostic criteria in Japan.
    Azemoto N; Abe M; Murata Y; Murakami H; Matsuura B; Hiasa Y; Onji M
    Intern Med; 2010; 49(12):1073-8. PubMed ID: 20558920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.
    Montano-Loza AJ; Lytvyak E; Hirschfield G; Hansen BE; Ebadi M; Berney T; Toso C; Magini G; Villamil A; Nevens F; Van den Ende N; Pares A; Ruiz P; Terrabuio D; Trivedi PJ; Abbas N; Donato MF; Yu L; Landis C; Dumortier J; Dyson JK; van der Meer AJ; de Veer R; Pedersen M; Mayo M; Manns MP; Taubert R; Kirchner T; Belli LS; Mazzarelli C; Stirnimann G; Floreani A; Cazzagon N; Russo FP; Burra P; Zigmound U; Houri I; Carbone M; Mulinacci G; Fagiuoli S; Pratt DS; Bonder A; Schiano TD; Haydel B; Lohse A; Schramm C; Rüther D; Casu S; Verhelst X; Beretta-Piccoli BT; Robles M; Mason AL; Corpechot C;
    J Hepatol; 2024 Oct; 81(4):679-689. PubMed ID: 38821360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes.
    Park Y; Cho Y; Cho EJ; Kim YJ
    Clin Mol Hepatol; 2015 Jun; 21(2):150-7. PubMed ID: 26157752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
    Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
    Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
    [No Abstract]   [Full Text] [Related]  

  • 27. Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications.
    Mapakshi S; Kramer JR; Richardson P; El-Serag HB; Kanwal F
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1677-1678. PubMed ID: 29410051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
    Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
    EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.
    Chang ML; Chen WT; Chan TM; Lin CY; Chang MY; Chen SC; Chien RN
    Front Immunol; 2022; 13():869018. PubMed ID: 35663951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA.
    Adejumo AC; Akhtar DH; Dennis BB; Cholankeril G; Alayo Q; Ogundipe OA; Kim D; Ahmed A
    Dig Dis Sci; 2021 May; 66(5):1461-1476. PubMed ID: 32535779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A brief review on prognostic models of primary biliary cholangitis.
    Chen S; Duan W; You H; Jia J
    Hepatol Int; 2017 Sep; 11(5):412-418. PubMed ID: 28913620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
    Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
    BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database.
    Goldberg DS; Lewis JD; Halpern SD; Weiner MG; Lo Re V
    Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):103-7. PubMed ID: 23124932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data.
    Pang JX; Ross E; Borman MA; Zimmer S; Kaplan GG; Heitman SJ; Swain MG; Burak KW; Quan H; Myers RP
    BMC Gastroenterol; 2015 Sep; 15():116. PubMed ID: 26362871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precirrhotic Primary Biliary Cholangitis with Portal Hypertension: Bile Duct Injury Correlate.
    Hu YF; Li SX; Liu HL; Du ZX; Wang SS; Chen MY; Wang L; Xiong QF; Zhong YD; Liu DX; Yang YF
    Gut Liver; 2024 Sep; 18(5):867-876. PubMed ID: 38623061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.